Related Experiment Video
Updated: Aug 4, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Amyotrophic lateral sclerosis: Lou Gehrig's disease
1University of Kansas School of Medicine, Wichita 67214-3199, USA.
American Family Physician
|April 8, 1999
Summary
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disease affecting motor neurons, leading to severe muscle weakness and disability. Research focuses on neuronal metabolism, glutamate, and neurotoxins to develop new treatments for this debilitating condition.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive neuromuscular disorder.
- It affects approximately 30,000 Americans, with an incidence of 1-2 per 100,000 people annually.
- ALS is typically diagnosed in middle age, affecting more men than women.
Observation:
- The disease presents with progressive muscle weakness, wasting, and fasciculations, impacting dexterity, gait, speech, and swallowing.
- Loss of upper and lower motor neuron function leads to complete disability, often necessitating ventilatory support and gastrostomy.
- Preserved functions include sphincter control, sensory perception, intellectual abilities, and skin integrity.
Findings:
- The exact etiology of ALS remains unknown.
- Current research investigates neuronal cell metabolism, particularly glutamate pathways, and the influence of neurotoxins and neurotrophic factors.
- New drug development is underway, targeting these underlying mechanisms.
Implications:
- Understanding ALS pathophysiology is crucial for developing effective therapeutic strategies.
- Targeting glutamate metabolism and neurotoxic pathways may offer novel treatment avenues.
- Continued research is essential for improving patient outcomes and managing complications associated with ALS.
Related Concept Videos
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...